PRME:NASDAQPrime Medicine, Inc. Analysis
Data as of 2026-08-15 - not real-time
$3.09
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Prime Medicine, Inc. trades at $3.09, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Across the trailing 30 sessions it lost 20.2%. With RSI at 47.1 the momentum picture is neutral, alongside a bullish MACD signal. Recent trading has carved out support near $2.72 and resistance around $3.32.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 127.4% above where the shares trade now. Revenue is growing at 3.5%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 79.1%, a beta of 2.27 and a maximum drawdown of 59.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: sell, at a conviction of 5 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 127.4% above where the shares trade now. Revenue is growing at 3.5%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 79.1%, a beta of 2.27 and a maximum drawdown of 59.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: sell, at a conviction of 5 out of 10.
Top Market Events
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program...Prime Medicine, Inc. NASDAQ:PRME is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc.Prime Medicine, Inc. NASDAQ:PRME ranks among the overlooked penny stocks to buy right now, supported by strong upside...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 3.59
- MACD momentum is positive
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 3.59
- Analyst targets imply +127.4% versus the current price
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- Analyst targets imply +127.4% versus the current price
- Negative return on equity of -373.3%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth3.50%
P/E Ratio-3.6
ROE-373.29%
ROA-46.52%
Debt/Equity282.54
P/B Ratio7.3
Op. Cash Flow$-156051008
Free Cash Flow$-75780000
Industry P/E29.8
Technical Analysis
TrendBearish
RSI47.1
Support$2.72
Resistance$3.32
MA 20$3.05
MA 50$3.26
MA 200$3.59
MACDBullish
VolumeStable
Fear & Greed Index95.98
Valuation
Target Price$7.03
Upside/Downside127.44%
GradeFair
TypeGrowth
Risk Assessment
Beta2.27
Volatility79.07%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.